Results 181 to 183 of about 4,821 (183)

Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?

Lancet, The
exaly  

Engineering of an Ultralong-Acting and Nonaggregating Dual Amylin and Calcitonin Receptor Agonist with Durable Efficacy in Obesity and Diabetes

Journal of Medicinal Chemistry
Nan Zheng, Rongfang Chen, Luying Yang, Pu Xu, Xueying Wang, Xin Sun, Yanxia Lin, Jinying Qiu, Xiao-xuan Su, You Wang, Leiming Wang, Weijun Shen   +11 more
openaire   +1 more source

Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial

Lancet, The
exaly